Improve the safety of an efficacious live-attenuated HIV-1 vaccine through unnatu

通过 unnatu 提高有效的 HIV-1 减毒活疫苗的安全性

• 批准号: 8837571
• 负责人: Jiantao Guo
• 金额: $ 46.49万
• 依托单位: UNIVERSITY OF NEBRASKA LINCOLN
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-05-01 至 2018-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8837571
• 关键词: Acquired Immunodeficiency Syndrome; Address; Amino Acids; Amino Acyl-tRNA Synthetases; Animal Model; Antigens; Attenuated; Bacteria; Biochemical; Biomedical Research; Bone Marrow; Charge; Clinic; Clinical; Clinical Trials; Code; Codon Nucleotides; Communicable Diseases; Development; Generations; Genome; Goals; HIV; HIV Genome; HIV-1; Health; Human; Immunization; In Vitro; Infection; Kinetics; Lead; Life; Liver; Macaca mulatta; Mammalian Cell; Mediating; Modality; Modeling; Mus; Nature; Nebraska; Pan Genus; Prevention; Protein Biosynthesis; Regulatory Element; Research; SIV; Safety; Technology; Testing; Thymus Gland; Time; Transfer RNA; Triplet Multiple Birth; Universities; Vaccine Research; Vaccines; Viral Genome; Virulence; Virus; clinical application; design; global health; improved; in vitro testing; in vivo; novel; novel strategies; pandemic disease; pathogen; prevent; rectal; spatiotemporal; stem; tool; transmission process

DESCRIPTION (provided by applicant): A safe and effective human immunodeficiency virus type one (HIV-1) vaccine is urgently needed to stem worldwide AIDS pandemic, but still remains elusive. Among all the HIV-1 vaccine modalities developed and tested thus far, nef-deleted live-attenuated HIV-1 vaccines (¿nef-LAV) confer the best protection against HIV-1 acquisition in simian immunodeficiency virus/rhesus macaque model of HIV-1 infection; however, its safety concerns preclude its clinical use. We at University of Nebraska-Lincoln in the past years have developed an unnatural amino acid (UAA)-mediated blank codon suppression approach to control HIV-1 protein biosynthesis. Our approach entails the manipulation of essential protein biosynthesis through blank codon (codons that do not encode a natural proteinogenic amino acid, such as nonsense triplet codon and frameshift codon) suppression that is precisely controlled by UAA that is not found in nature. We applied this technology to HIV-1 vaccine research by introducing several sets of blank codons coding for UAA into virus genome to control HIV-1 replication. We successfully demonstrated that we could turn HIV-1 replication on and off in vitro. We hypothesize that our novel strategy to allow live-attenuated HIV-1 to replicate only in the presence of the three artificial regulatory elements that are not found in nature (novel ¿nef-LAV) will greatly improve the safety of conventional ¿nef-LAV while still maintains its good efficacy against HIV-1 acquisition. We therefore propose to test this hypothesis with three specific aims. Specific Aim 1, to control the replication of novel ¿nef-LAV in vitro, of which we will apply and further optimize blank codon suppression strategy and incorporate suppression tRNA-aaRS pair into the HIV-1 genome to control HIV-1 replication by supplementing or withdrawing UAA in mammalian cells in vitro. Specific Aim 2, to control novel ¿nef-LAV replication in vivo, of which we will compare and contrast the in vivo replication capacity and kinetics of the novel ¿nef-LAV that has passed multi-cycle replication tests in vitro in the Specific Aim 1 with conventional ¿nef-LAV using humanized- BLT mice. The results of the Specific Aim 2 will be used to further optimize the novel ¿nef-LAV virus design and development in the Specific Aim 1. Specific Aim 3, novel ¿nef-LAV in vivo protection, of which we will compare the protection rate of novel ¿nef-LAV vs. conventional ¿nef-LAV against HIV-1 rectal challenge using hu-BLT mice. Since our strategy can greatly improves the safety of ¿nef-LAV by providing additional safety locks on HIV-1, it makes the modified ¿nef-LAV practical in clinical trial. In addition, the approaches/tools that are developed and further optimized in this research can be applied to the generation of vaccines against other pathogenic viruses or bacteria, and therefore is expected to exert broader impact on vaccine research.

描述（由申请人提供）：迫切需要一种安全有效的人类免疫缺陷病毒1型（HIV-1）疫苗来阻止全球范围内的艾滋病流行，但仍然难以捉摸。在迄今开发和测试的所有HIV-1疫苗模式中，nef-缺失的HIV-1减毒活疫苗（¿nef-LAV）在猴免疫缺陷病毒/恒河猴HIV-1感染模型中对HIV-1获得的保护效果最好；然而，其安全性问题阻碍了其临床应用。在过去的几年里，我们在内布拉斯加大学林肯分校开发了一种非天然氨基酸（UAA）介导的空白密码子抑制方法来控制HIV-1蛋白的生物合成。我们的方法需要通过空白密码子（不编码天然蛋白质生成氨基酸的密码子，如无义三联体密码子和移码密码子）抑制必需蛋白质的生物合成，这种抑制由自然界中未发现的UAA精确控制。我们将这一技术应用于HIV-1疫苗的研究，通过在病毒基因组中引入几组编码UAA的空白密码子来控制HIV-1的复制。我们成功地证明了我们可以在体外开启和关闭HIV-1的复制。我们假设，我们的新策略允许减毒活HIV-1仅在自然界中不存在的三种人工调控元件（novel¿nef-LAV）存在的情况下复制，将大大提高传统¿nef-LAV的安全性，同时仍然保持其对HIV-1获得的良好功效。因此，我们建议用三个具体目标来检验这一假设。具体目的1，在体外控制新型¿nef-LAV的复制，我们将在哺乳动物细胞中应用并进一步优化空白密码子抑制策略，通过补充或提取UAA，将抑制tRNA-aaRS对纳入HIV-1基因组，控制HIV-1的复制。特异性目标2，控制新型¿nef-LAV在体内的复制，我们将在特异性目标1中与传统的¿nef-LAV进行比较和对比，这种新型¿nef-LAV在体外通过了多周期复制试验，使用人源化BLT小鼠。特异性目标2的结果将用于进一步优化特异性目标1中的新型¿nef-LAV病毒的设计和开发。特异性目的3，新型nef-LAV体内保护，我们将比较新型nef-LAV与传统nef-LAV对hu-BLT小鼠直肠HIV-1攻击的保护率。由于我们的策略可以通过为HIV-1提供额外的安全锁，大大提高¿nef-LAV的安全性，这使得改进的¿nef-LAV在临床试验中具有实用性。此外，本研究开发和进一步优化的方法/工具可应用于生产针对其他致病性病毒或细菌的疫苗，因此有望对疫苗研究产生更广泛的影响。